New vitamin D receptor ligands

Bibliography

• CHAWLA A, REPA JJ, EVANS RM, MANGELSDORF DJ: Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 294:1866–1870.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the impact of thenuclear receptor superfarnily.
   Google Scholar
• CARLBERG C: Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling. Ear. Biochem. (1995) 231:517–527.
   Google Scholar
• MORAS D, GRONEMEYER H: The nuclear receptor ligand-binding domain: structure and function. Can: Opin. Cell Biol. (1998) 10:384–391.
   PubMed Web of Science ®Google Scholar
• GLASS CK, ROSENFELD MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes & Dev. (2000) 14:121–141.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on nuclear receptorcoregulators.
   Google Scholar
• MACIAS GONZALEZ M, CARLBERG C: Cross-repression, a functional consequence of the physical interaction of non-liganded nuclear receptors and POU domain transcription factors." Biol. Chem. (2002) 277:18501–18509.
   PubMed Web of Science ®Google Scholar
• POLLY P, HERDICK M, MOEHREN U et al.: VDR-Alien: a novel, DNA-selective vitamin D3 receptor-corepressor partnership. FASEB J. (2000) 14:1455–1463.
   PubMed Web of Science ®Google Scholar
• HERDICK M, BURY Y, QUACK M et al.: Response element- and coactivator-mediated conformational change of the vitamin D3 receptor permits sensitive interaction with agonists. Mol. Pharmacol (2000) 57:1206–1217.
   PubMed Web of Science ®Google Scholar
• RACHEZ C, GAMBLE M, CHANG C-PBet al: The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitutive functionally distinct complexes. Ma Cell. Biol. (2000) 20:2718–2726.
   Web of Science ®Google Scholar
• CARLBERG C: Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. (2003) 88:274–281.
   PubMed Web of Science ®Google Scholar
• •Most recent overview on VDR-vitamin D analogue relationship.
   Google Scholar
• MORK HANSEN C, BINDERUP L, HAMBERG KJ, CARLBERG C: Vitamin D and cancer: effects of2-3 la,25(nD) n and its, -, analogs on growth control and tumorigenesis. Front. Biosci. (2001) 6:D820–D848.
   Web of Science ®Google Scholar
• BROWN AJ: Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. (2001) 38:S3–S19.
   PubMed Web of Science ®Google Scholar
• CARLBERG C, BENDIK I, WYSS A et al:Two nuclear signalling pathways for vitamin D. Nature (1993) 361:657–660.
   PubMed Web of Science ®Google Scholar
• CHESKIS B, FREEDMAN LP: Ligand modulates the conversion of DNA-bound vitamin D3receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Cell. Biol. (1994) 14:3329–3338.
   Google Scholar
• SCHRADER M, MOLLER KM, NAYERI S, KAHLEN JP, CARLBERG C: VDR-T3R receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature (1994) 370:382–386.
   PubMed Web of Science ®Google Scholar
• SCHRADER M, MOLLER KM, CARLBERG C: Specificity and flexibility of vitamin D signaling. Modulation of the activation of natural vitamin D response elements by thyroid hormone. j Biol. Chem. (1994) 269:5501–5504.
   Google Scholar
• SCHRADER M, BENDIK I, BECKER-ANDRE M, CARLBERG C: Interaction between retinoic acid and vitamin D signaling pathways. J. Biol. Chem. (1993) 268:17830–17836.
   PubMed Web of Science ®Google Scholar
• NORMAN AW: Receptors for la,25(OH)2D3: past, present, and future.J. Bone Mineral Res. (1998) 13:1360–1369.
   PubMed Web of Science ®Google Scholar
• NORMAN AW, OKAMURA WH, BISHOP JE, HENRY HL: Update on biological actions of la, 25 (OH)2-vitamin D3 (rapid effects) and 24R,25 (OH) 2-vitamin D3. Ma Cell. Endocrinol (2002) 197:1–13.
   PubMed Web of Science ®Google Scholar
• PROFER K, RACZ A, LIN GC, BARS ONY J: Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J. Biol. Chem. (2000) 275:41114–41125.
   PubMed Web of Science ®Google Scholar
• SIMONCINI T, HAFEZI- MOGHADAM A, BRAZIL DP et al: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinosito1-3-OH kinase. Nature (2000) 407:538–541.
   PubMed Web of Science ®Google Scholar
• KABAT MM, BURGER W, GUGGINO S et al.: Total synthesis of 25-hydroxy-16,23E-diene vitamin D3 and la,25-dihydroxy-16,23E-diene vitamin D3: separation of genomic and non-genomic vitamin D activities. Bioorg. Med. Chem. (1998) 6:2051–2059.
   PubMed Web of Science ®Google Scholar
• FREEDMAN LP: Multimeric coactivator complexes for steroid/nuclear receptors. Trends Endocrinol Metal,. (1999) 10:403–407.
   PubMed Web of Science ®Google Scholar
• BOUILLON R, OKAMURA WH, NORMAN AW: Structure-function relationships in the vitamin D endocrine system. Endocr. Rev (1995) 16:200–257.
   PubMed Web of Science ®Google Scholar
• •Still the most comprehensive overview on vitamin D analogues.
   Google Scholar
• BURY Y, RUF D, HANSEN CM et al: Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases.J Invest. Dermatol (2001) 116:785–792.
   PubMed Web of Science ®Google Scholar
• •VDR-ligand complex stability over time.
   Google Scholar
• JOHNSON CS, HERSHBERGER PA, BERNARDI RJ, MCGUIRE TF, TRUMP DL: Vitamin D receptor: a potential target for intervention. Urology (2002) 60:123–130.
   PubMed Web of Science ®Google Scholar
• EISMAN JA: Genetics of osteoporosis. Endocr: Rev (1999) 20:788–804.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, ADORINI L: The coming of age of la,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Ma Med. (2002) 8:174–179.
   PubMed Web of Science ®Google Scholar
• COLSTON KW, MACKAY AG, JAMES SY et al: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol (1992) 44:2273–2280.
   PubMed Web of Science ®Google Scholar
• EVANS TR, COLSTON KW, LOFTS FJ et al.: A Phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. Cancer (2002) 86:680–685.
   Google Scholar
• QUACK M, CARLBERG C: Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol. Pharmacol. (1999) 55:1077–1087.
   PubMed Web of Science ®Google Scholar
• TOELL A, POLLY P, CARLBERG C: All natural DR3-type vitamin D response elements show a similar functionality M vitro. Biochem. (2000) 352:301–309.
   Google Scholar
• JONES G, STRUGNELL SA, DELUCA HF: Current understanding of the molecular actions of vitamin D. Physiol. Rev (1998) 78:1193–231.
   PubMed Web of Science ®Google Scholar
• WU S, REN S, CHEN H al: Intracellular vitamin D binding proteins: novel facilitators of vitamin D-directed transactivation [In Process Citation]. Mol. Endocrinol. (2000) 14:1387–1397.
   PubMedGoogle Scholar
• NAYERI S, DANIELSSON C, KAHLEN JP et al.: The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Oncogene (1995) 11: 1853-1858.
   Google Scholar
• •The first report on promoter selectivity of vitamin D analogues.
   Google Scholar
• HISATAKE J-I, O'KELLY J, USKOKOVIC MR, TOMOYASU S, KOEFFLER HP: Novel vitamin D3 analog, 21- (3-methy1-3-hydroxy-buty0-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood (2001) 97:2427–2433.
   PubMed Web of Science ®Google Scholar
• ROCHEL N, WURTZ JM, MITSCHLER A, KLAHOLZ B, MORAS D: Crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Md. Cell(2000) 5:173–179.
   PubMed Web of Science ®Google Scholar
• ••The VDR crystal structure.
   Google Scholar
• TOCCHINI-VALENTINI G, ROCHEL N, WURTZJM, MITSCHLER A, MORAS D: Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci USA (2001) 98:5491–5496.
   PubMed Web of Science ®Google Scholar
• ••There is only one agonistic VDRconformation.
   Google Scholar
• NAYERI S, KAHLEN JP, CARLBERG C: The high affinity ligand binding conformation of the nuclear 1,25-dihydroxyvitamin D3 receptor is functionally linked to the transactivation domain 2 (AF-2). Nucleic Acids Res. (1996) 24:4513–4518.
   PubMed Web of Science ®Google Scholar
• PELEG S, NGUYEN C, WOODARD BT,LEE J-K, POSNER GH: Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A-ring-modified analogs. Mol. Endocrinol. (1998) 12:525–535.
   PubMedGoogle Scholar
• CARLBERG C, QUACK M, HERDICK M et al.: Central role of VDR conformations for understanding selective actions of vitamin D3 analogues. Steroids (2001) 66:213–221.
   PubMed Web of Science ®Google Scholar
• VAN DEN BEMD G-JCM, POLS HAP, BIRKENHAGER JC, VAN LEEUWEN JPTM: Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. Proc. Natl. Acad. Sri. USA (1996) 93:10685–10690.
   PubMed Web of Science ®Google Scholar
• CORNELLA I, PEREZ SESTELO J, MOURPSIO A, SARANDESES LA: Synthesis of new 18-substituted analogues of calcitriol using a photochemical remote functionalization. J. Org. Chem. (2002) 67:4707–4714.
   PubMed Web of Science ®Google Scholar
• WU Y, SABBE K, DE CLERCQ P et al.: Vitamin D3: synthesis of seco C-9,11, 21 - trisnor-17-m ethyl- la, 25-dihydroxyvitamin D3 analogues. Bioorg. Med. Chem. Lett (2002) 12:1629–1632.
   Google Scholar
• RODRIGUEZ DS, KANZLER S, REISCHL W et al.: A novel class of aromatic vitamin D analogs. Curr: Pharm. Des. (2000)•6:749–754.
   Google Scholar
• KITTAKA A, SUHARA Y, TAKAYANAGI H et al.: A concise and efficient route to 2a-(omega-hydroxyalkoxy)-1a,25-dihydroxyvitam in D3: remarkably high affinity to vitamin D receptor. Org. Lett. (2000) 2:2619–2622.
   PubMed Web of Science ®Google Scholar
• SHEVDE NK, PLUM LA, CLAGETT-DAME M et al.: A potent analog of la,25-dihydroxyvitamin D3 selectively induces bone formation. Proc. Nati Acad. Sri. USA (2002) 99:13487–13491.
   PubMed Web of Science ®Google Scholar
• SICINSKI RR, PRAHL JM, SMITH CM, DELUCA HF: New la,25-dihydroxy-19-57.norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2- methylene analogues. Med. Chem. (1998)•41:4662–4674.
   Google Scholar
• SICINSKI RR, ROTKIEWICZ P, KOLINSKI A et al.: 2-Ethyl and 2-ethylidene analogues of la,25-dihydroxy-19-norvitamin D3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J. Med. Chem. (2002) 45:3366–3380.
   PubMed Web of Science ®Google Scholar
• POSNER GH, LEE JK, WANG Q et at Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone la,25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. Med. Chem. (1998) 41:3008–3014.
   Google Scholar
• MASUDA S, JONES G: Vitamin D analogs-drug design based on proteins involved in vitamin D signal transduction. Curl: Drug Targets Immune Endocr. Metabol. Disord. (2003) 3:43–46.
   PubMedGoogle Scholar
• BOEHM ME FITZGERALD p, ZOU A et al.: Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol. (1999) 6:265–275.
   PubMedGoogle Scholar
• •First report on non-steroidal vitamin D analogues.
   Google Scholar
• SWANN SL, BERGH J, FARACH-CARSON MC, OCASIO CA, KOH JT: Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. Am. Chem. Soc. (2002) 124:13795–13805.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA M, RAAKA BM, SAMUELS JUT, ABAGYAN R: Rational discovery of novel nuclear hormone receptor antagonists. Pim Natl. Acad. Sri. USA (2000) 97:1008–1013.
   PubMed Web of Science ®Google Scholar
• BURY Y, STEINMEYER A, CARLBERG C: Structure-activity relationship of carboxylic ester antagonists of the vitamin D3 receptor. Mol. Pharmacol. (2000) 58:1067–1074.
   PubMed Web of Science ®Google Scholar
• •The first true vitamin D antagonist.
   Google Scholar
• HERDICK M, STEINMEYER A, CARLBERG C: Antagonistic action of a 25-carboxylic ester analogue of la,25-dihydroxyvitamin D3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. Biol. Chem. (2000) 275:16506–16512.
   Web of Science ®Google Scholar
• OZONO K, SAITI M, MIURA D et al.: Analysis of the molecular mechanism for the antagonistic action of a novel la,25-dihydroxyvitamin D3 analogue toward vitamin D receptor function. I. Biol. Chem. (1999) 274:32376–32381.
   Web of Science ®Google Scholar
• TOELL A, GONZALEZ MM, RUF D et al.: Different molecular mechanisms of vitamin D3 receptor antagonists. Mol. Pharmacol. (2001) 59:1478-1485. Comparison of Schering and Teijin vitamin D antagonists.
   Google Scholar
• VAISANEN S, PERAKYLA M, KARKKAINEN JI, STEINMEYER A, CARLBERG C: Critical role of helix 12 of the vitamin D3 receptor for the partial agonism of carboxylic ester antagonists. Biol. (2002) 315:229-238. Molecular action of vitamin D antagonists.
   Google Scholar
• BULA CM, BISHOP JE, ISHIZUKA S, NORMAN AW: 25-Dehydro-la-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol.Endocrinol. (2000) 14:1788–1796.
   PubMedGoogle Scholar
• MCDONNELL DP: The molecular pharmacology of SERMs. Trends Endocrinol Metab. (1999) 10:301–311.
   PubMed Web of Science ®Google Scholar
• HERDICK M, STEINMEYER A, CARLBERG C: Carboxylic ester antagonists of la,25-dihydroxyvitamin D3show cell-specific actions. Chem. Biol. (2000) 7:885–894.
   PubMedGoogle Scholar
• NORMAN AW, MANCHAND PS, USKOKOVIC MR et al.: Characterization of a novel analog of la,25(OH)2-vitamin D3 with two side chains: interaction with its nuclear receptor and cellular actions. Med. Chem. (2000) 43:2719–2730.
   Web of Science ®Google Scholar
• BURY Y, HERDICK M, USKOKOVIC MR, CARLBERG C: Gene regulatory potential of la,25-dihydroxyvitamin D3 analogues with two side chains.' Cell. Biochem. (2001) 81:179–190.
   Google Scholar
• HERDICK M, CARLBERG C: Agonist-triggered modulation of the activated and silent state of the vitamin D3 receptor by interaction with co-repressors and co-activators. J. Mo/. Biol. (2000) 304:793–801.
   PubMed Web of Science ®Google Scholar
• KABAT MM, RADINOV R: The practical synthesis of vitamin D analogs: a challenge for process research. Carr: Opin. Drug Discov. Bevel. (2001) 4:808–833.
   PubMedGoogle Scholar
• •A good review on the use of the Lythgoe approach to vitamin D analogues.
   Google Scholar
• FERNANDEZ-GACIO A, VITALE C, MOURINO A: Synthesis of new aromatic (C17-C20)-locked side-chain analogues of calcitriol (1a,25-dihydroxyvitamin D3). J. Org. Chem. (2000) 65:6978–6983.
   PubMed Web of Science ®Google Scholar
• HANAZAWA T, INAMORI H, MASUDA T, OKAMOTO S, SATO F: Efficient and practical synthesis of the A-ring precursor of l9-nor- la,25-dihydroxyvitamin D3 and its [13C]- or [2H]-labeled derivative. Org. Lett. (2001) 3:2205–2207.
   PubMed Web of Science ®Google Scholar
• HIYAMIZU H, OLL H, INOMOTO Y et al.: A concise enantioselective synthesis of a key A-ring synthon for la-hydroxyvitamin D3compounds. Org. Lett. (2001) 3:473–475.
   PubMed Web of Science ®Google Scholar
• POSNER GH, WANG Q, HANG et al: Conceptually new sulfone analogues of the hormone la,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Med. Chem. (1999) 42:3425–3435.
   Web of Science ®Google Scholar
• POSNER GH, CRAWFORD K, SIU-CALDERA ML et al.: Conceptually new 20-epi-22-oxa sulfone analogues of the hormone la,25-dihydroxyvitamin D3: synthesis and biological evaluation. " Med. Chem. (2000) 43:3581–3586.
   Google Scholar
• ANDREWS DR, BARTON DHR, HESSE RH: Synthesis of 25-hydroxy- and la,25-dihydroxy-vitamin D3 from vitamin D2 (calciferoll." Org. Chem. (1986) 51:4819–4828.
   Google Scholar
• CALVERLEY MJ: Synthesis of MC903, a biologically active vitamin D metabolite analogue. Tetrahedron Lett. (1987) 43:4609–4619.
   Google Scholar
• HAMMOND ML, MOURINO A, OKAMURA WH: Sigmatropic rearrangement of vinylallenes: a novel route to the 1-hydroxyvitamin D system. " Am. Chem. Soc. (1978) 100:4907–4908.
   Web of Science ®Google Scholar
• VANALSTYNE EM, NORMAN AW, OKAMURA WH: 7,8-Cis geometric isomers of the steroid hormone la,25-dihydroxyvitamin D3. J. Am. Chem. Soc. (1994) 116:6207–6216.
   Web of Science ®Google Scholar
• ZHU G-H, OKAMURA WH: Synthesis of vitamin D (calciferol). Chem. Rev (1995) 95:1877–1952.
   Web of Science ®Google Scholar
• ••Excellent review on the synthesis of vitamin Danalogues.
   Google Scholar
• MASCAREICIAS JL, SARANDESES LA, CASTEDO L, MOURINO A: Palladium-catalysed coupling of vinyl triflates with enynes and its application to the synthesis of 1a,25-dihydroxyvitamin D3. Tetrahedron (1991) 20/21:3485–3489.
   Google Scholar
• OKAMURA WH, AURRECCOCHEA JM, GIBBS RA, NORMAN AW: Synthesis and biological activity of 9,10-dehydrovitamin D3 analogues: stereoselective preparation of 6I3-vitamin D vinylallenes and a concise enynol synthesis for preparing the A-ring. Org. Chem. (1989) 54:4072–4083.
   Web of Science ®Google Scholar
• TROST BM, DUMAS J, VILLA M: New strategies for the synthesis of vitamin D metabolites via Pd-catalyzed reactions. Am. Chem. Soc. (1992) 114:9836–9845.
   Web of Science ®Google Scholar